Little is known about patient preferences for selection of chronic hepatitis B (CHB) treatment. This issue is important as it affects the therapeutic choices available for patients and, in the long term, the health of CHB patients.
Methods
The study was a questionnaire-led survey directed at patients attending a CHB follow-up clinic. Patients were asked questions regarding their knowledge on CHB treatment, preferred route and frequency of administration, duration of treatment, cost, adverse events, viral resistance, efficacy and whether treatment options were discussed with doctors. Patients were also asked to rank their priorities when selecting treatment for CHB. In addition, a summary of the profile of current agents was shown to patients who were then asked to select their preferred therapy. Finally, patients were asked questions regarding their willingness to pay for CHB treatment and expectations of treatment. Questionnaires were self-administered and statistical analysis was performed using SPSS (version 10.0).
Results
Lamivudine was the best-known drug among patients. Only 30% of patients were treatment-naive. Most patients preferred oral therapy with once-daily dosing and a fixed duration of treatment. Drug efficacy was considered the most important factor in drug selection. When shown the profile of the different drugs available for the treatment of CHB, entecavir was the preferred choice of therapy. The majority of patients were willing to spend no more than S$10 (USD 8) daily for therapy with expectation of cure for their disease. Overall, 92% of patients would follow doctor's recommendations.
Conclusions
Patients’ preferences are important in evaluating drug selection for CHB.
References
1.
LavanchyD.Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol2005; 34Suppl 1: S1–S3.
2.
LiawY-F, LeungN., KaoJ-HAsian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int2008; 2: 263–283.
3.
HannH-W, HanS-H, BlockT.M.Symptomatology and health attitudes of chronic hepatitis B patients in the USA. J Viral Hepat2008; 15: 42–51.
4.
LeungC.M., WongW.H., ChanK.H.Public awareness of hepatitis B infection: a population-based telephone survey in Hong Kong. Hong Kong Med J2010; 16: 463–469.
5.
TaylorV.M., JacksonJ.C., ChanN., KuniyukiA., YasuiY.Hepatitis B knowledge and practices among Cambodian American women in Seattle, Washington. J Community Health2002; 27: 151–163.
6.
ShiauR., BoveF., HenneJ., ZolaJ., FangT., FernyakS.Using survey results regarding hepatitis B knowledge, community awareness and testing behaviour among Asians to improve the San Francisco Hep B free campaign. J Community Health2012; 37: 350–364.
7.
KieslerD.J., AuerbachS.M.Optimal matches of patient preferences for information, decision-making and interpersonal behavior: evidence, models and interventions. Patient Educ Couns2006; 61: 319–341.
de HaesH.Dilemmas in patient centeredness and shared decision making: a case for vulnerability. Patient Educ Couns2006; 62: 291–298.
10.
StevensonF.A., BarryC.A., BrittenN., BarberN., BradleyC.P.Doctor-patient communication about drugs: the evidence for shared decision making. Soc Sci Med2000; 50: 829–840.
11.
SidaniS., EpsteinD., MirandaJ.Eliciting patient treatment preferences: A strategy to integrate evidence-based and patient-centered care. Worldviews Evid Based Nurs2006; 3: 116–123.
12.
SayR.E., ThomsonR.The importance of patient preferences in treatment decisions–challenges for doctors. BMJ2003; 327: 542–545.
13.
SchneiderU., UlrichV.The physician-patient relationship revisited: the patient's view. Int J Health Care Finance Econ2008; 8: 279–300.
14.
SchoutenB.C., MeeuwesenL., TrompF., HarmsenH.A.Cultural diversity in patient participation: the influence of patients’ characteristics and doctors’ communicative behaviour. Patient Educ Couns2007; 67: 214–223.
15.
ChongC.A., ChenI.J., NaglieG., KrahnM.D.How well do guidelines incorporate evidence on patient preferences?J Gen Intern Med2009; 24: 977–982.
16.
LeeK.H., AungM.O., LimS.G.Are physicians following guidelines? A survey of hepatitis B management strategies. Hepatol Int.2013; 7: 451–459.
17.
DanY.Y., AungM.O., LimS.G.The economics of treating chronic hepatitis B in Asia. Hepatol Intl2008; 2: 284–295.
18.
WaiC.T., MakB., ChuaW.Misperceptions among patients with chronic hepatitis B in Singapore. World J Gastroenterol2005; 11: 5002–5005.
19.
LiawY.F., KaoJ.H., PiratvisuthT.Asia-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int2012; 6: 531–561.
